Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for symbols : Jagx save search
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 6.09%
H: 7.88%
C: 0.68%
fda drug diarrhea health designation application crofelemer submission
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -15.16%
H: 1.78%
C: -18.62%
diarrhea cancer trial therapy
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.03%
H: 1.67%
C: -1.27%
breast health life symposium cancer pharmaceuticals family study
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.7%
H: 3.0%
C: -9.45%
rare health license revenue pharmaceuticals commercialization crofelemer agreement store
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published: 2023-11-01 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.45%
H: 1.57%
C: -1.0%
patent health treatment
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Published: 2023-10-18 (Crawled : 13:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -4.27%
H: 8.4%
C: 5.92%
drug conference association care pharmaceuticals
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.19%
H: 3.51%
C: -2.33%
life cancer pharmaceuticals study
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Published: 2023-09-21 (Crawled : 12:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.28%
H: 4.8%
C: 2.03%
health research adhd
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published: 2023-09-13 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.71%
H: 3.71%
C: -6.39%
patent japan health treatment
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published: 2023-09-12 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -1.74%
np-300 drug candidate institute diarrhea health application family funding
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
Published: 2023-09-11 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -2.94%
conference health presentation growth
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Published: 2023-08-30 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -2.28%
H: 0.5%
C: -4.94%
rare disease crofelemer
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published: 2023-08-17 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -4.06%
H: 0.41%
C: -2.97%
diarrhea health cancer treatment family crofelemer trial
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published: 2023-08-09 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.85%
H: 0.84%
C: -10.4%
np-300 drug candidate diarrhea health application family funding
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Published: 2023-08-08 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
fda drug disease health microvillus treatment application crofelemer
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published: 2023-08-07 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.2%
H: 3.33%
C: 0.63%
diarrhea breast cancer crofelemer study
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published: 2023-08-01 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.02%
H: 0.67%
C: -2.84%
fda drug diarrhea health treatment application crofelemer
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-07-26 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 2.57%
H: 11.58%
C: 6.27%
diarrhea health approval treatment trial
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
Published: 2023-06-28 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.53%
H: 6.69%
C: 6.28%
fda drug disease health microvillus application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.